GlaxoSmithKline and Roche announce co-development and co-promotion agreement

10-Dec-2001

Basel and London, December 7, 2001 -- GlaxoSmithKline plc and Roche announced that they have signed an agreement to co-develop and co-promote ibandronate, currently in Phase III clinical development, for the treatment and prevention of Postmenopausal Osteoporosis.

Given the promising clinical trial results, Roche will be able to take full advantage of the potential of this exciting and promising medicine by collaborating with a strong development and marketing partner. Combining Roche and GSK's development, marketing and sales capabilities will provide the maximum added value for patients and prescribers.

Terms of Agreement

Under the terms of the agreement, Roche and GSK will share the future development and registration costs for the product and Roche will receive certain milestone payments from GSK. Roche will account for all sales of the product. Both companies will share profits. The companies plan to file the first drug applications with the US Food and Drug Administration and in Europe in 2002. Subject to local legal requirements, Roche and GSK plan to co-promote ibandronate in all countries, except Japan.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances